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Abstract 
Background: Type 2 diabetes is commonly characterized by insulin deficiency and decreased sensitivity of insulin 
receptors, leading to a chronic state of hyperglycemia in individuals. Disease progression induces changes in the 
immune profile that engenders a chronic inflammatory condition. Thiazolidinedione (TDZ) drugs, such as Pioglitazone 
(Pio), aid in controlling disease symptoms. While the mechanisms by which Pio controls hyperglycemia are beginning 
to be understood, relatively little is known about the effects of Pio on suppression of the systemic immune pheno‑
type, attributed to visceral adipose tissue and macrophages.
Methods: Here, we utilize the recently developed BBDZR/Wor type 2 diabetes rat model to test our hypothesis that 
a selective in vivo growth of CD3+T cells in the spleen contributes to the increase in T lymphocytes, including Tregs, 
independent of visceral adipose tissue. We investigated the systemic effects of Pio on multifactorial aspects of the 
disease‑induced immune phenotype both in vivo and in vitro in normal, non‑diabetic animals and in disease.
Results: Our work revealed that Pio reversed the lymphopenic status of diabetic rats, in part by an increase in CD3+ T 
lymphocytes and related subsets. Moreover, we found evidence that Pio caused a selective growth of newly differen‑
tiated T lymphocytes, based on the presence of recent thymic emigrants in vivo. To investigate effects of Pio on the 
inflammatory milieu, we examined the production of the signature cytokines TNF‑α and IL‑1β and found they were 
reduced by Pio‑treatment, while the levels of IL‑4, an anti‑inflammatory mediator, were significantly increased in a 
Pio‑dependent manner. The increase in IL‑4 production, although historically attributed to macrophages from visceral 
adipose tissue under other conditions, came also from CD3+ T lymphocytes from the spleen, suggesting splenocytes 
contribute to the Pio‑induced shift towards an anti‑inflammatory phenotype.
Conclusions: We show for the first time that Pio treatment significantly suppresses the systemic inflammatory status 
in the BBDZR/Wor type 2 diabetes rat model by the selective growth of newly differentiated CD3+ T cells and by 
increasing CD3+IL‑4 production in immigrant spleen lymphocytes.
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Background
Due to a persistent rise in incidence, type 2 diabe-
tes affects 29.1 million Americans, or 9.3  % of the US 
population, and the disease ranks as the 7th leading 
cause of death in 2010 [1–3]. In 2012, diabetes and its 
complications accounted for over $245 billion in direct 
medical costs and indirect expenses related to wages and 
lost work. Type 2 diabetes represents 90  % of the total 
cases diabetes mellitus nationwide, and current treat-
ment options range from exercise and diet modification 
to pharmaceutical interventions that augment insulin 
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sensitivity and alleviate hyperglycemia [1]. While many 
of the pathological consequences of type 2 diabetes are 
related to chronic hyperglycemia, the onset and progres-
sion of this disease also leads to a dysregulation of the 
immune response, resulting in chronic inflammation [4]. 
Therefore, in addition to combating the effects of glucose 
toxicity, effective treatments must concurrently mitigate 
the activation of inflammatory mediators in order to pre-
vent immune-mediated pathology [4].
Thiazolidinediones (TZDs) are a common class of 
drugs prescribed to patients with type 2 diabetes. TZDs, 
such as rosiglitazone and pioglitazone, are used to lower 
systemic glucose concentration by insulin sensitivity [5, 
6]. These compounds function as peroxisome prolifera-
tor-activated receptor gamma (PPARγ) agonists [7]. Acti-
vation of PPARγ in tandem with the retinoid X receptor 
modulates regulatory effects on inflammatory target 
genes [8, 9]. The cumulative result is decreased insulin 
resistance [10–13], modification of adipocyte differen-
tiation [11, 12, 14, 15], decreased leptin levels [16], and 
decreased mean arterial pressure [13].
The present study aimed to assess the mechanisms 
responsible for systemic effects of Pioglitazone (Pio) on 
the immunoregulation of lymphocytes and monocytes. 
For these studies, we analyzed secondary immune organs 
in the recently developed BBZDR/Wor type 2 diabetes 
rat model, thus allowing us to examine effects of Pio on 
altered systemic immune function associated with the 
disease status. Past studies have examined anti-inflam-
matory mechanisms of PPARγ agonists, such as Pio 
and Ciglitazone [17–19], and report down-regulation of 
macrophages [20, 21] and modulation of T cell activa-
tion [22–24]. However, most of these studies focus on 
analyses of the macrophage and regulatory T cell popu-
lation in adipose tissue and not in immune organs such 
as the spleen and liver. Here, we demonstrate a selec-
tion for in  vivo growth of T lymphocytes, indicated by 
an increase in recent thymic emigrants, as a result of Pio 
treatment in BBDZR/Wor rats. Furthermore, to investi-
gate extra-splenic contributions, we studied the in  vitro 
effects of Pioglitazone in normal, non-diabetic, spleno-
cytes and demonstrate an increase in T cells, including 
regulatory T cells, and in monocytes, independent of the 
presence of visceral adipose tissue.
Methods
Animals
Male obese and lean (non-diabetic) littermates BBZDR/
Wor rats were purchased from Biomedical Research 
Models (Worchester, MA). Obese: diabetic model; lean 
littermates: non-diabetic, control group. Any obese 
rat that did not show glucose levels  >250  mg/dL were 
excluded from the study. Five rats from each group 
received a daily intraperitoneal (i.p., 1  mL final vol-
ume) injection of 25 mg/kg Pioglitazone or vehicle (5 % 
DMSO) for 2  months, as described in [19], followed 
by sacrifice for analyses. All animal experiments were 
approved by The University of Tennessee Health Science 
Center Institutional Animal Care and Use Committee.
Glucose measurements
Rats underwent glucose measurements by glucose strip 
readings, as we previously described [25]. Rats glucose 
levels >250 mg/dL were considered diabetic [19].
Tissue culture experiments
Splenocytes and hepatocytes were isolated by physi-
cal disruption using the back end of a syringe on a 
70  μM nylon strainer. Cell suspension was washed 
and Red Blood Cell (RBC) contaminants were elimi-
nated using RBC Lysis Buffer (BioLegend, San Diego, 
CA, USA) following manufacturer’s instructions. Cells 
(5.0 ×  105 cells/mL) were cultured in a 24-well plate in 
RPMI/10  % FBS/1  % Pen/Strep media. In vitro condi-
tions included ±25 μM Pioglitazone (Pio; Sigma-Aldrich, 
St. Louis, MO, USA) for 24  h. Ex vivo cell activation 
was done using Phorbol 12-myristate 13-acetate (PMA; 
Sigma-Aldrich) at a concentration of 100 ng/mL for 6 h. 
Golgi Stop® was added (1 μL per 1 mL of culture) for the 
last 4 h of incubation prior to harvest to inhibit cytokine 
transport.
Surface molecule labeling
Cell suspensions were washed in Staining Buffer 
(PBS/1  % FBS) prior to labeling. Cells were labeled for 
30 min protected from light on ice bucket. Once labeled 
cells were washed multiple times with Staining Buffer 
and analyzed immediately. The following anti-rat anti-
bodies were used: anti-CD3 AF-647, anti-CD4 PE-Cy7, 
anti-CD11b/c APC, anti-CD25 FITC, and anti-CD31 
Biotin/Streptavidin Brilliant Violet 421 (SA-bv421), all 
from BioLegend (San Diego, CA, USA). For each anti-
body we used the respective Immunoglobulin G (IgG) 
isotype control. In addition, we used single label control 
Abc™ Capture Beads (Life Technologies). Data acquired 
in BD Biosciences LSRII Flow Cytometer and analyses 
were done using FlowJo vX.10.0.6 software (Tree Star, 
OR).
Intracellular assay
Following cell surface labeling, cells were fixed using eBi-
oscience FoxP3 Fixation/Permeabilization Buffer (eBio-
sciences), followed by intracellular labeling for 30  min 
with either anti-rat FoxP3 PE or isotype control PE. 
Cells were washed multiple times prior acquisition and 
analysis.
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Western blot
Cells were lysed in 25  μL of Lysis Buffer as previously 
described [26]. Protein concentrations were determined 
using Pierce™ BCA Protein Assay Kit (Thermo Scien-
tific). A total of 30 μg of denatured protein was used for 
each sample loaded in a Novex® 4–12 % Tris–Glycine Gel 
(Life Technologies). Membrane was blocked in 20 mL of 
5  % BSA in TBS-Tween 20 and incubated overnight at 
4  °C in 1:1000 PPARγ rabbit monoclonal antibody (Cell 
Signaling Technologies) followed by 1:1000 anti-rabbit 
secondary antibody solution for 1  h at RT. Once com-
pleted, the membrane was washed and probed for β-actin 
as control (Cell Signaling Technologies). SuperSignal 
West Pico Chemiluminiscent Substrate (Thermo Scien-
tific) was used. Densitometry analysis was done using 
Kodak Molecular Imager.
Statistics
Mann–Whitney U tests were used for Western Blot data 
and student t tests were used for flow cytometry analy-
sis. Data was analyzed using GraphPad software (Graph-
Pad Software, Inc., La Jolla, CA, USA). Values of p < 0.05 
were considered significant.
Results
Pio eliminates hyperglycemia without a reduction 
in adipose tissue
Recently, we provided evidence that Pio improved retinal 
insulin signaling in the BBZDR/Wor type 2 diabetes rat 
model in a PPARγ-dependent manner [19]. Pio reduced 
TNF-α and SOCS3-activated insulin resistance pathways 
in the retina and protected against diabetic retinopathy 
[19]. As a next step, we wanted to assess the systemic 
immunomodulatory effects of Pio on BBZDR/Wor rats 
under the same treatment conditions.
First, we confirmed the efficacy of Pio in reduc-
ing hyperglycemia in this model. Ten obese diabetic 
BBZDR/Wor rats and ten lean non-diabetic littermates 
were randomized into treatment or control, yield-
ing four groups (diabetic, diabetic  +  Pio, non-diabetic, 
non-diabetic + Pio). For the five rats in each of the two 
treatment groups, 25  mg/kg of Pio was injected intra-
peritoneally each day for 2  months. Figure  1a shows a 
dramatic reduction in blood glucose levels in the dia-
betic rats after Pio treatment (p < 0.05). Consistent with 
established mechanisms of Pio action, glucose reduc-
tion was not associated with loss of body mass (diabetic 
versus non diabetic: 383  ±  14.8 versus 105.3  ±  20.8; 
p =  0.0002; diabetic +  Pio versus diabetic: 93.4 ±  28.1 
versus 383  ±  14.8; p  =  0.0140). Moreover, Pio-treated 
rats gained weight compared to untreated diabetic rats 
(Fig. 1b, diabetic versus non diabetic: 623 ± 12.3 versus 
457 ±  29.7; p =  0.0002; diabetic +  Pio versus diabetic: 
820.8 ± 75.9 versus 623 ± 12.3; p = 0.0018). These results 
confirm that the effect of Pio on glucose normalization 
and the immunophenotype is independent of loss of adi-
pose tissue.
Pio mitigates lymphopenia in BBZDR/Wor rats
In addition to hyperglycemia and obesity, diabetic 
BBZDR/Wor rats have reduced numbers of circulating T 
lymphocytes compared to their non-diabetic lean litter-
mates. Using splenocytes as an indicator of the systemic 
immunophenotype, we next determined differences in 
the relative levels of CD3+ and CD3+CD4+ splenocyte 
subtypes between the groups. As shown in Table  1 and 
Fig. 1c, the percentage of CD3+ and CD3+CD4+ T cells 
among splenocytes is lower in the untreated diabetic rats 
compared to untreated non-diabetic lean controls [CD3+: 
10.7 % ± 3.0 versus 86.4 % ± 2.8, respectively, p = 0.0087; 
CD3+CD4+: 11.0 % ± 8.4 versus 53.1 % ± 10, respectively, 
p  =  0.0043; (mean  ±  SD)]. Treatment of non-diabetic 
rats with Pio had no significant effect on the percentage 
of CD3+ T cells (86.2  % ±  0.5, p =  0.4474) and a mar-
ginally, but not significant increase on the percentage of 
CD3+CD4+ T cells (p  =  0.05). However, treatment of 
the diabetic rats with Pio significantly increased the per-
centage of both CD3+ (64.3 % ± 3.3 versus 10.7 % ± 3.0, 
p = 0.0135) and CD3+CD4+ T cells (27.3 % ± 3.9 versus 
11.0 % ± 8.4, p = 0.0302). This increase reversed the lym-
phopenia observed in the diabetic obese rats compared 
to their non-diabetic littermates.
In vivo increase of T lymphocytes by Pio correlates 
with increase in recent thymic emigrants
To investigate the origin of this Pio-stimulated popu-
lation of lymphocytes, we labeled splenocytes in each 
group with anti-CD31 monoclonal antibody. Positivity 
of CD31 among CD3+CD4+ T lymphocytes is a marker 
of recent thymic emigration (reviewed in [27]). Figure 1d 
demonstrates a significant increase in the percent-
age of CD3+CD4+CD31+ splenocytes after Pio treat-
ment in both diabetic (13.2 % ± 1.0 versus 34.2 % ± 2.3, 
p =  0.0011) and non-diabetic rats (34.1  % ±  2.6 versus 
47.4  %  ±  0.6, p  <  0.005). These results suggest a Pio-
dependent amelioration of lymphopenic status in the 
BBZDR/Wor diabetic rats due, at least in part, to lym-
phocyte emigration from the thymus after Pio treatment.
In vivo decrease in pro‑inflammatory cytokines (TNF‑a 
and IL‑1β) and increase in anti‑inflammatory cytockine, 
IL‑4, after Pio treatment
As has been extensively shown and reviewed [28–34], 
states of obesity and hyperglycemia upregulate pro-
inflammatory cytokines both locally and systemically. 
To confirm that the diabetic BBZDR/Wor rats exhibit 
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these pathologic changes, we investigated the percent-
age of CD3+ splenocytes producing the pro-inflam-
matory cytokines TNF-ɑ and IL-1β. As expected, 
diabetic rats showed an increase in the percentage of 
CD3+TNF-ɑ-producing cells compared to the non-
diabetic (11.7  %  ±  1.2 versus 4.4  %  ±  1.3, p  <  0.005, 
Fig. 2a). Furthermore, our data suggests splenic lympho-
cytes contribute, at least part, to the pro-inflammatory 
cytokine milieu. Our results suggest that at least part of 
that action, in the case of Pioglitazone, is due to reduc-
tion of the CD3+ T cells that produce TNF-α and IL-1β. 
Diabetic rats treated with Pio had a lower percentage of 
CD3+TNF-α-producers (1.8 % ± 1.7 versus 11.7 % ± 1.2 
in controls; p  <  0.05, Fig.  2a). Similarly, CD3+IL-1β-
producers were reduced from 5.0 % ± 1.4 to 1.3 % ± 1.6 
(p < 0.05, Fig. 2b).
Fig. 1 Pioglitazone eliminates hyperglycemia and mitigates lymphopenia in BBZDR/Wor diabetic rats. a, b Pioglitazone‑dependent reduction in 
glucose levels is independent of weight. BBDZR/Wor diabetic and non‑diabetic (littermates) rats were injected daily intraperitoneally with either 
25 mg/kg pioglitazone or vehicle (5 % DMSO) for 2 months. Each group had 5 rats (a *p < 0.05, #p < 0.0002; b #p = 0.0002, *p = 0.0018). c Pioglita‑
zone restores diabetic‑induced lymphopenic status. Splenocytes from all four groups were examined for the percentage of CD3+CD4+ T cells using 
rat anti‑CD3 Alexa Fluor 647 and anti‑CD4 PE‑Cy7 antibodies. Upper representative pseudocolor plot of 1 rat per condition. Lower quantitation of the 
flow cytometry analysis (n = 3; *p = 0.0087, #p = 0.0043). d In vivo increase in percentage of T lymphocytes is partly attributed to increase in recent 
thymic emigrants. Gated CD3+ T cells were examined for CD4 and CD31 immunoreactivity by using rat anti‑CD4 PE‑Cy7 and rat anti‑CD31 Biotin/
Streptavidin bv421, respectively. Upper representative plot of 1 rat per condition. Lower quantitation analysis (n = 3; #p < 0.005, *p = 0.0011)
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Next, we addressed if the reduction in pro-inflamma-
tory mediators was accompanied by an increase in anti-
inflammatory cytokines, such as IL-4. First, we show 
BBZDR/Wor diabetic rats have significantly diminished 
levels of CD3+IL-4+ splenocytes compared to non-
diabetics (1.1  % ±  0.1 versus 13.5  % ±  1.3, respectively 
p < 0.005, Fig. 2c). As expected, there was a shift towards 
an anti-inflammatory phenotype with a significant 
increase in CD3+IL-4-producers in the spleen in both the 
non-diabetic and the diabetic treated groups (non-dia-
betic: 13.5 % ± 1.3 to 22.2 % ± 1.9, p < 0.0005; diabetic: 
1.1  % ±  0.1 to 30.4  % ±  15, p  <  0.05; Fig.  2c). Previous 
reports showed the source of IL-4 production was from 
a macrophage population within adipose tissue, termed 
M2 [35, 36]. To investigate the relative contribution of 
the CD3+ T cell population to the total IL-4 production, 
we analyze for the total IL-4-producer cells, comprising 
both CD3+ and CD3neg cells. Our results revealed that 
CD3+ T cells are large contributors, in both the non dia-
betic and diabetic groups, as shown in Fig. 2c. CD3+ con-
tribution to the IL-4-producers in the non-diabetic + Pio 
group was 43.9 versus 80.2 % in the diabetic + Pio group. 
Together, these results implicate CD3+ splenocytes as 
contributors to the loss of anti-inflammatory signaling 
Table 1 Splenocyte immunophenotypes after treatment with Pioglitazone in vitro and in vivo
Splenocytes were labeled with rat anti-CD3 AF-647, anti-CD4 PE-Cy7, and anti-CD25 FITC. Results are % ± SD, n = 3
In vitro non-diabetic + Pio versus non-diabetic: * p = 0.0085, # p = 0.0006, ¶ p = 0.0022
In vivo diabetic versus non-diabetic (1): * p = 0.0087, # p = 0.0043, ¶ p = 0.0040
Diabetic + Pio versus Diabetic (2): * p = 0.0135, # p = 0.0302, ¶ p = 0.0178
In vitro In vivo
Non‑diab. Non‑diab. + Pio Non‑diab. Non‑diab. + Pio Diabetic Diabetic + Pio
CD3+ 14.4 % ± 0.4 17.8 % ± 1.0* 86.4 % ± 2.8 86.2 % ± 0.5 10.7 % ± 3.0* 64.3 % ± 3.3*
CD3+CD4+ 12.7 % ± 0.7 3.7 % ± 0.3# 53.1 % ± 10 50.0 % ± 8.8 11 % ± 8.4# 27.3 % ± 3.9#
CD3+CD4+CD25+ 6.6 % ± 0.4 33.1 % ± 3.4¶ 12.4 % ± 1.8 19.0 % ± 0.5 4.6 % ± 2.1¶ 36.2 % ± 7.1¶
Fig. 2 Reduced inflammatory phenotype in pio‑treated diabetic BBDZR/Wor rats. Splenocytes from all four groups were cultured for 6 h ex vivo 
in the presence of Phorbol 12‑myristate 13 acetate (PMA) at a concentration of 100 ng/mL. Golgi Plug was added for the last 4 h of treatment to 
inhibit protein transport. Cells were harvested and analyzed for different cytokines. Gates were established by using respective anti‑cytokine isotype 
control. Upper panels are representative from n = 3 and lower panels (bar graphs) represent % ± SD. a Results for CD3+TNF‑α‑producers (#p < 0.005, 
p < 0.05); b CD3+IL‑1β‑producers (*p < 0.05); and c CD3+IL‑4 and total IL‑4 producers (#p < 0.0005, *p < 0.005, ¶p < 0.05)
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associated with diabetes. Furthermore, Pio treatment 
is able to recover critical regulatory balance in the 
immunophenotype.
Pio reduces CD11b/c+ population in BBZDR/Wor rats
Recent literature has placed a significant emphasis on 
macrophages, particularly those in adipose tissue, as 
drivers of obesity-related inflammation and subsequent 
insulin resistance [37, 38]. Specifically, there is a decrease 
in anti-inflammatory M2 macrophages and a reciprocal 
increase in pro-inflammatory M1 macrophages.  These 
M1 macrophages are defined as CD11c+, which have 
been shown to increase in adipose tissue with obesity 
[39]. We labeled Pio-treated and untreated splenocytes 
with an anti-CD11b/c antibody that reacts with a com-
mon epitope within the CR3 complement receptor (C3bi) 
shared by CD11b and CD11c. This epitope is non-exclu-
sive, as it is present in monocytes, dendritic cells, mac-
rophages, and other immune cells. The percentage of 
splenocytes expressing this marker was higher in diabetic 
rats compared to non-diabetic littermates (19 versus 
8  %; 2.4-fold increase, Fig.  3a). After Pio treatment, the 
percentage of CD11b/c+ splenocytes decreased to lev-
els comparable to non-diabetic controls (diabetic: 10  %, 
non-diabetic: 9  %). Interestingly, Pio treatment did not 
significantly affect levels of this marker among treated 
and untreated non-diabetic rats (9 and 8 %, respectively). 
Next, we analyzed these CD11b/c+ cells by examination 
of CD4 positivity. Although the percentage of CD11b/
c+ cells was higher in diabetic rats, a much smaller per-
centage of these cells were CD4+ (23  % in diabetic ver-
sus 41 % in non-diabetic, Fig. 3b). Pio treatment partially 
reversed this imbalance by increasing the percentage of 
CD4+ among the CD11b/c+ population in the diabetic 
rats from 23 to 33 %.
Reduction of CD4+ T lymphocytes, increase in regulatory T 
cells (CD3+CD4+CD25+FoxP3+) and modulation of CD11b/
c+ cells after Pio treatment in vitro
After establishing that Pio treatment of BBZDR/Wor dia-
betic rats mitigates several aspects of the pro-inflamma-
tory immunophenotype, we investigated which specific 
effects were mediated by extra-splenic mechanisms and 
which were due to direct effects by splenocytes. Spleno-
cytes from non-diabetic rats were cultured in  vitro for 
24 h in the presence or absence of 25 μM Pio. Western 
blot analysis showed no statistical difference (p =  0.35; 
n = 3) in the levels of PPARγ protein relative to β-actin 
in splenocytes cultured with or without Pio (Fig.  4a, 
left). For comparison, we cultured hepatocytes from the 
same rats under the same conditions.  Figure  4a, right 
demonstrates that levels of PPARγ protein levels in 
hepatocytes treated with Pio although higher, are not sig-
nificant (p = 0.05, n = 3).
Next, we examined the percentage of total CD3+ T 
lymphocytes in splenocytes cultured in the presence of 
Pio. As we found in  vivo, the percentage of CD3+ cells 
present in splenocyte cultures increased after treat-
ment (17.8  %  ±  1.0 treated versus 14.4  ±  0.4 control, 
p = 0.0085) (shown in Table 1 and Fig. 4b). Furthermore, 
there was a prominent down-regulation of the CD4 co-
receptor among CD3+ cells, as 3.7 % ± 0.3 of Pio-treated 
splenocytes exhibited a CD3+CD4+ phenotype com-
pared to 12.4  %  ±  0.6 in untreated cells (p  =  0.0006). 
These results suggests that the in  vivo increase in 
CD3+CD4+ cells in the diabetic rat spleens was in large 
part due to recent thymic emigration after Pio treat-
ment. Additionally, Pio treatment exerted significant 
effects without upregulating PPARγ protein levels. We 
Fig. 3 Pioglitazone alters CD11b/c+ population in splenocytes of 
BBZDR/Wor rats. a Splenocytes from all groups were labeled with 
rat anti‑CD11b/c APC. b Gated population in panel a examined for 
expression of CD4. Figures are representative of 2‑pooled splenocytes 
per condition
Page 7 of 11Gao et al. Diabetol Metab Syndr  (2015) 7:72 
further characterized the CD3+CD4+ subset to evalu-
ate the percentage of CD3+CD4+ T lymphocytes immu-
noreactive against CD25. Upregulation of the IL-2Rα 
chain, CD25, is associated with an activated and immu-
noregulatory phenotype. We hypothesized that CD25 
expression would be increased and partially responsible 
for the anti-inflammatory transition after Pio treatment. 
Figure  4b shows the percentage of CD3+CD4+CD25+ 
T lymphocytes in untreated versus Pio-treated cells. 
In the untreated samples, an average of 6.6  %  ±  0.4 of 
CD3+CD4+ cells co-expressed CD25 (Table 1). However, 
Pio-treated splenocytes showed an increased percentage 
of CD3+CD4+CD25+ T cells: 33.1 % ± 3.4 (p = 0.0022). 
To further explore this immunomodulation we moni-
tored the percentage of cells that were FoxP3 positive, 
a well-established marker for immunoregulatory phe-
notype associated with relative immunosuppression 
[40–42]. While both groups showed a large population 
of CD3+CD4+CD25+FoxP3+ cells, this subpopulation 
increased from 44.7 % ± 2.5 to 51.5 % ± 2.1 (p = 0.0237) 
after Pio treatment. Collectively, this data suggests treat-
ment with Pio favors an anti-inflammatory phenotype.
Lastly, we determined the effects of Pio on other 
immune populations by labeling Pio-treated and 
Fig. 4 In vitro effects of Pioglitazone treatment in non‑diabetic splenocytes. a Left, Similar levels of PPARγ in splenocytes with and without Piogl‑
itazone treatment. Right, Increase in PPARγ levels in Pio‑treated hepatocytes compared to untreated. Splenocytes or hepatocytes were cultured 
in the presence or absence of Pioglitazone 25 μM for 24 h followed by cell lysis treatment for Western blot analysis. Results are shown as bar 
graphs, dark gray represent untreated, white with black stripes represent Pio‑treated. Graphs show the ratio of PPARγ to β‑actin as arbitrary units 
(A.U.); n = 3. Upper part shows blot results in presence (+Pio) or absence (untreated) of treatment. b Top panels show the percentage of CD3+ and 
CD3+CD4+ T lymphocytes in untreated and Pio‑treated splenocytes; n = 3. Cultured splenocytes were harvested and surface labeled with anti‑CD3 
Alexa Fluor 647, ‑CD4 PE‑Cy7 and ‑CD25 FITC antibodies prior fixation and permeabilization for intracellular FoxP3‑PE labeling. Mid panel shows 
percentage of CD3+CD4+CD25+ T cells followed by FoxP3 analysis of the gated population. Histogram shows percentage of FoxP3+ cells from the 
CD3+CD4+CD25+ gate; n = 3. Gray histogram depicts isotype control; black line depicts anti‑rat FoxP3 labeling. Figures are representation of n = 3. 
At the right there is quantitation of each panel in bar graph: *p = 0.0006, #p = 0.002, ¶p = 0.0237
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untreated splenocytes with anti-CD11b/c as before. 
Figure 4c shows a significant increase in the percentage 
of cells with a CD11b/c+ phenotype in untreated versus 
Pio-treated cells (4.92  %  ±  0.09 versus 5.73  %  ±  0.11, 
respectively; p = 0.0007).
Discussion
Two decades ago, Lehmann et  al. [6], identified thiazo-
lidinedione (TZD) derivatives as potential anti-diabetic 
agents in animal models of type 2 diabetes. These drugs 
exhibit high affinity for the peroxisome proliferator-acti-
vated receptor gamma (PPARγ) ligand. PPARγ belongs to 
a family of nuclear receptors that play central roles in the 
regulation of metabolic homeostasis, including modu-
lation of lipids, glucose, and bone remodeling [43–45]. 
This class of receptor is considered a regulator of adi-
pose tissue inflammation and its activation increases the 
expression of adiponectin enhancing insulin sensitivity. 
Pioglitazone (Pio) is a PPARγ agonist used for the treat-
ment of type 2 diabetes [46, 47]. While Pio has exten-
sively been studied in resident cells within adipose tissue, 
the effects of this drug are poorly understood in second-
ary immune organs, such as the spleen and liver. Our 
work demonstrates that Pio may reverse some of the type 
2 diabetes-associated pathogenesis by a de novo increase 
of CD3+CD4+CD31+ T lymphocytes, with a concomi-
tant reduction of pro-inflammatory mediators (TNF-α, 
IL-1β) and augmentation of anti-inflammatory cytokines 
(IL-4) in the BBDZR/Wor type 2 diabetes rat model.
Obesity, implicated in the etiology of type 2 diabetes, 
causes a chronic low-grade systemic inflammation con-
tributing to metabolic dysfunction (reviewed in [48]). 
Clinically, type 2 diabetes is evidenced by a rise in blood 
glucose due to faulty insulin-dependent signaling mech-
anisms. Pio-dependent glucose normalization did not 
require weight loss in the BBZDR/Wor type 2 diabetes 
rat model (Fig.  1a, b), suggesting that PPARγ regulates 
additional mechanisms besides adipose tissue and body 
weight. The increase in adipose tissue observed in type 2 
diabetes has led to focus investigations of the pro-inflam-
matory mediators associated with visceral adipose tissue 
(VAT). Two major cell populations have been investi-
gated in the past, VAT regulatory T cells [49–53] and 
macrophages [23, 35, 48, 54–56]. First, Cipolleta et  al., 
recently showed regulatory T cells expressing PPARγ 
suppress inflammation and regulates insulin resistance 
[49, 50]. Clark and colleagues [57] demonstrated Cigli-
tazone, another PPARγ agonist, enhances regulatory 
T cells in  vitro. Accordingly, our work shows upregula-
tion of CD25 in Pio-treated splenocytes in vitro. A large 
portion of the CD25+ cells were positive for the FoxP3 
transcription factor, considered a master regulator of 
natural regulatory T cells [40–42]. We and others, have 
previously shown enhancement of the FOXP3 transcrip-
tion factor in human cells correlates with increases in 
suppressive capacity of regulatory cells [58, 59]. Thus we 
speculate this population makes a major contribution to 
dampening of inflammation. We also speculate that the 
remaining FoxP3neg population exhibits an activated or 
induced regulatory T cell phenotype.
A number of reports have established that monocytes 
recruited to adipose tissue become resident macrophages 
[60, 61]. Macrophages accumulate in adipose tissue in 
both obese patients and rodents [35]. This prompted the 
studies to establish the linkage between an inflammatory 
phenotype characterized by increased levels of TNF-α 
and other pro-inflammatory cytokines and insulin resist-
ance. Resident macrophages in adipose tissue of lean 
rodents showed an anti-inflammatory phenotype, or M2, 
whereas those of obese rodents showed a pro-inflamma-
tory, or M1, phenotype. M1 macrophages displayed high 
levels of CD11c in their surface. While the mechanisms 
responsible for recruitment and establishment of sub-
types of macrophages in VAT in diabetes are beginning 
to be understood, there is relatively little understanding 
of comparable mechanisms in other immune organs. 
Similar to the VAT findings, we observed a higher per-
centage of CD11b/c+ cells in splenocytes from diabetic 
rats compared to non-diabetics (Fig. 3a). This population 
decreased in the Pio-treated rats. Moreover, the popula-
tion was not altered in the Pio-treated non-diabetic rats. 
These results suggests that diabetes-dependent inflam-
mation causes an increase in the CD11b/c+ in spleno-
cytes and that Pio-treatment reduces this population to 
baseline levels, as evidenced by the lack of effects in the 
untreated and treated non-diabetic rats.
Much of the pro-inflammatory cytokine milieu is 
attributed to the M1 population in VAT [39, 54, 62]. 
Our work revealed that non-VAT components are also 
contributors to the inflammation. We found CD3+ T 
lymphocytes in diabetic rats produced higher levels of 
TNF-α and IL-1β, both pro-inflammatory mediators, 
compared to non-diabetic counterparts (Fig. 2a, b). Both 
pro-inflamatory cytokines were significantly reduced in 
splenocytes of Pio-treated rats, suggesting that Pio sup-
presses cell immune responses in non-adipose tissue. Of 
particular note is the reduction in IL-1β, as this cytokine 
is implicated in the destruction of pancreatic β-cells [63, 
64]. Reduction of pro-inflammatory cytokines may not be 
sufficient to control the disease. This may also be accom-
panied by an increase in anti-inflammatory cytokines, 
such as IL-4. Classically, IL-4 serves as an immunoregu-
latory cytokine and as a mitogen for the proliferation 
of cells with an anti-inflammatory phenotype [65–67]. 
It is important to determine the source of the IL-4 pro-
duction. Our work revealed that in the spleen, CD3+ T 
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lymphocytes, not CD3neg cells, were a major source of 
IL-4 (Fig. 2c). Together, this work suggests splenic com-
ponents are contributors to the control of inflammation 
in Pio-treated diabetic rats.
Using our BBZDR/Wor rat model, we found Pio 
treatment in  vivo caused an increase in recent thymic 
emigrants, which may contribute to the increase in per-
centage of total T lymphocytes, resulting in alleviation 
of lymphopenia observed in untreated BBZDR/Wor rats. 
Previous work in type 1, not type 2, diabetes rat models 
showed reduction of recent thymic emigrants is due, in 
part to defective intrathymic selection leading to auto-
immunity [68]. Subsequent reports by Ramanathan and 
colleagues [69] confirmed these results. Rodent mod-
els of obesity based on mutations in leptin-coding gene 
(Lepob/Lepob) have shown thymic involution that reduces 
T cell responses and the number of T cell emigrants to 
the periphery [70]. This suggests that there is a com-
pound effect of diabetes coupled with obesity. Here, we 
show first, type 2 diabetic BBZDR/Wor rats have reduced 
frequency of recent thymic emigrants and second, a Pio-
dependent increase in recent thymic emigrants in dia-
betic rats, independent of their body weight. Our work 
suggests the effects are Pio-dependent as we observed an 
increase in recent thymic emigrants in non diabetic rats 
with normal blood glucose levels. Still, we cannot rule 
out there might be compound effects by the reduction in 
blood glucose in addition to Pio-treatment, as shown in 
the diabetic + Pio group. Recent work suggests Pio and 
other TZDs can act in PPARγ dependent and independ-
ent manner (reviewed in [71]). This new data provides an 
additional complexity level to our study and others as it 
demonstrated reduction in the pro-inflammatory milieu 
could happen independent of PPARγ signaling in the 
presence of Pio and other TZDs. Our work shows the 
presence of PPARγ in the rats hepatocytes and spleno-
cytes. Interestingly, our study opens new investigations 
to integrate multiple signaling pathways that could facili-
tate type 2 diabetes therapeutics. Some provocative sci-
entific concerns are if other blood glucose lowering drugs 
will exhibit similar in vivo results; and how does insulin 
receptor signaling is affected by Pio. There is a need for 
more biochemical studies to understand the basis of Pio’s 
actions.
Our investigation suggests there is promising potential 
for immune modulation therapy in type 2 diabetes using 
the TZD-derivative, Pioglitazone. More work is required 
to elucidate how the PPARγ-signaling pathway, via Pio, 
interacts with multiple cellular pathways, including sur-
face receptors, signals driving proliferative and suppres-
sive responses, and transcriptional regulators. Future 
studies aimed at investigating how to improve immune 
surveillance and control the complications of type 2 
diabetes could provide new strategies for improving the 
quality of life of diabetic patients.
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